Subtype
Malignant Uterine Neoplasm
CI-CAN-00005955Explore in graph →
823 active trials7 approved drugs44 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00005955Explore in graph →
Clinical trials
3,290 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (333)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07078838 | Tirzepatide in Women With Obesity and Endometrial Intra-epithelial Neoplasia or Grade 1 Endometrial Cancer | not yet recruiting | Phase 2 | 40 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT06084780 | Intestinal & Multivisceral Transplantation for Unresectable Mucinous Carcinoma Peritonei (TRANSCAPE)(TRANSCAPE) | not yet recruiting | Phase 2 | 20 | Case Comprehensive Cancer CenterOTHER | 1 | Sep 24, 2026 |
| clinicaltrials |
| NCT07832227 | Imlunestrant/Abemaciclib/Selinexor in Ovarian and Endometrial(SIERRA) | not yet recruiting | Phase 2 | 60 | Dana-Farber Cancer InstituteOTHER | 0 | Sep 21, 2026 | clinicaltrials |
| NCT07576725 | Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial | not yet recruiting | Phase 2 | 50 | Fred Hutchinson Cancer CenterOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT07820358 | Semaglutide, Weight Loss, and LNG-IUD for Conservative Treatment of Endometrial Atypical Hyperplasia and Grade 1 Endometrial Cancer(SWIFT) | not yet recruiting | Phase 2 | 48 | The Methodist Hospital Research InstituteOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT07811375 | Perioperative Adebrelimab for Locally Advanced Cervical Cancer(ADE-LACC) | not yet recruiting | Phase 2 | 35 | Anhui Provincial HospitalOTHER_GOV | 1 | Sep 10, 2026 | clinicaltrials |
| NCT05521997 | Glutaminase Inhibition and Chemoradiation in Advanced Cervical Cancer | not yet recruiting | Phase 2 | 42 | Washington University School of MedicineOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT07793318 | TR115 in ARID1A-Mutated Advanced Solid Tumors | not yet recruiting | Phase 2 | 50 | Tarapeutics Science Inc.INDUSTRY | 1 | Aug 28, 2026 | clinicaltrials |
| NCT07753824 | A Phase II Study of Ivonescimab Combined With Intraperitoneal Paclitaxel in Patients With High-Grade Metastatic Appendiceal Adenocarcinoma (AA) | not yet recruiting | Phase 2 | 30 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 27, 2026 | clinicaltrials |
| NCT07349641 | A Study of Weight Loss Intervention With Tirzepatide and Progestin Intrauterine Device to Treat Endometrial Hyperplasia and Grade 1 Endometrial Cancer | not yet recruiting | Phase 2 | 55 | National Cancer Institute (NCI)NIH | 1 | Aug 26, 2026 | clinicaltrials |
| NCT07781150 | Mazdutide Plus LNG-IUS for Fertility-Sparing Treatment of AEH or Early Endometrial Cancer(MELIA) | not yet recruiting | Phase 2 | 128 | Tongji HospitalOTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT07770100 | Concurrent Immunotherapy and Systemic Therapy With Stereotactic Body Radiation Therapy (SBRT) for Stage IV Cancers (COINSSS IV) | not yet recruiting | Phase 2 | 35 | Mark BernardOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT07752875 | A Study of LG00313112 in Participants With Advanced Solid Malignancies Harboring a TP53 Y220C Mutation | not yet recruiting | Phase 1 / Phase 2 | 250 | LG ChemINDUSTRY | 0 | Aug 7, 2026 | clinicaltrials |
| NCT07738315 | Elemene Liposomes in Endometrial Cancer | not yet recruiting | Phase 2 | 212 | Women's Hospital School Of Medicine Zhejiang UniversityOTHER | 1 | Jul 31, 2026 | clinicaltrials |
| NCT07737795 | Evaluating the Addition of OK-1 Weekly Paclitaxel in Patients With Endometrial Cancer | not yet recruiting | Phase 2 | 66 | University of OklahomaOTHER | 1 | Jul 30, 2026 | clinicaltrials |
| NCT07714070 | Orlistat Plus Progestin for Fertility-Sparing Treatment of Endometrial Cancer or Atypical Hyperplasia(PKUPH-ORLPP-EC) | not yet recruiting | Phase 2 | 48 | Peking University People's HospitalOTHER | 1 | Jul 20, 2026 | clinicaltrials |
| NCT07668284 | COQ10 and Vitamin E for Off-Target Radiation Toxicity | not yet recruiting | Phase 1 / Phase 2 | 200 | University of NebraskaOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT07665684 | Samuraciclib in Combination With Gemcitabine/Nab-Paclitaxel in Patients With Metastatic Basal-Like Pancreatic Cancer(SONIC) | not yet recruiting | Phase 1 / Phase 2 | 67 | University Health Network, TorontoOTHER | 1 | Jun 24, 2026 | clinicaltrials |
| NCT07649174 | Cadonilimab Plus Chemotherapy in LACC: A Prospective, Multicenter, Randomized Phase II Trial | not yet recruiting | Phase 2 | 134 | Obstetrics & Gynecology Hospital of Fudan UniversityOTHER | 1 | Jun 16, 2026 | clinicaltrials |
| NCT07634601 | Elacestrant With Everolimus for the Treatment of Recurrent Advanced or Metastatic ER-Positive Endometrial Cancer | not yet recruiting | Phase 2 | 50 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jun 9, 2026 | clinicaltrials |
| NCT07627620 | Camrelizumab Combined With Famitinib Malate and Chemotherapy for Treatment of Recurrent/ Metastatic Cervical Cancer | not yet recruiting | Phase 2 | 54 | Hunan Cancer HospitalOTHER | 0 | Jun 4, 2026 | clinicaltrials |
| NCT07617818 | QL1706 Combined With Cisplatin/Paclitaxel as Neoadjuvant Therapy for Cervical Cancer | not yet recruiting | Phase 2 | 50 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 0 | Jun 1, 2026 | clinicaltrials |
| NCT07605247 | Tirzepatide in the Treatment of Endometrial Cancer(TREAT-EC) | not yet recruiting | Phase 2 | 30 | Rutgers, The State University of New JerseyOTHER | 0 | May 22, 2026 | clinicaltrials |
| NCT07522697 | Inavolisib for PIK3CA Mutated Advanced Endometrial Cancer: MITO END-4(MITO END-4) | not yet recruiting | Phase 2 | 48 | National Cancer Institute, NaplesOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT07516210 | Adaptive Radiotherapy for Safe Hypofractionation(ART-Hypo) | not yet recruiting | Phase 2 | 264 | Centre hospitalier de l'Université de Montréal (CHUM)OTHER | 1 | Apr 7, 2026 | clinicaltrials |
| NCT07497074 | JSKN033 Combination Therapy in Subjects With Advanced Cervical Cancer | not yet recruiting | Phase 2 | 78 | Jiangsu Alphamab Biopharmaceuticals Co., LtdINDUSTRY | 1 | Mar 27, 2026 | clinicaltrials |
| NCT07453394 | QLS5132 Combination Therapy in Advanced Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 626 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 0 | Mar 6, 2026 | clinicaltrials |
| NCT07450963 | Cadonilimab Combined With RT in LACC Patients Ineligible for CCRT | not yet recruiting | Phase 2 | 45 | Ruijin HospitalOTHER | 0 | Mar 5, 2026 | clinicaltrials |
| NCT07368985 | Pembrolizumab and Lenvatinib in Patients With High Risk Locally Advanced Cervix Cancer | not yet recruiting | Phase 2 | 87 | Prof. Dr. Remi A. NoutOTHER | 1 | Jan 27, 2026 | clinicaltrials |
| NCT07369986 | Immunotherapy for Surgery Avoidance in Vulnerable dMMR Endometrial Cancer(IMMUNE-SAVE) | not yet recruiting | Phase 2 | 30 | Women's Hospital School Of Medicine Zhejiang UniversityOTHER | 0 | Jan 27, 2026 | clinicaltrials |
| NCT07363330 | A Phase II Study of Utidelone With Toripalimab in Advanced Cervical Cancer | not yet recruiting | Phase 2 | 32 | Zhongnan HospitalOTHER | 1 | Jan 26, 2026 | clinicaltrials |
| NCT07348861 | A Phase II Study of Neoadjuvant Sacituzumab Tirumotecan in Combination With Iparomlimab and Tuvonralimab in Locally Advanced Cervical Cancer | not yet recruiting | Phase 2 | 25 | Zheng MinOTHER | 1 | Jan 16, 2026 | clinicaltrials |
| NCT05106127 | Safety Lead-In Study of a Repurposed Drug Added to the Combination of Len Plus Pem | not yet recruiting | Phase 2 | 28 | Evergreen Therapeutics, Inc.INDUSTRY | 0 | Dec 8, 2025 | clinicaltrials |
| NCT07244965 | Neoadjuvant Ivonescimab Plus Chemotherapy Followed by Concurrent Chemoradiotherapy in High-Risk Locally Advanced Cervical Cancer | not yet recruiting | Phase 2 | 42 | Women's Hospital School Of Medicine Zhejiang UniversityOTHER | 1 | Nov 24, 2025 | clinicaltrials |
| NCT07088731 | Clinical Study to Evaluate the Efficacy and Safety of Nab-Paclitaxel Combined With Cisplatin and Sintilimab in Neoadjuvant Treatment of Locally Advanced Cervical Cancer | not yet recruiting | Phase 2 | 180 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Sep 22, 2025 | clinicaltrials |
| NCT07177716 | Efficacy and Safety of LB1410 Plus Lenvatinib With or Without LB4330 in Advanced Recurrent/Metastatic Cervical Cancer | not yet recruiting | Phase 2 / Phase 3 | 120 | L & L Bio Co., Ltd., Ningbo, ChinaINDUSTRY | 1 | Sep 17, 2025 | clinicaltrials |
| NCT07172217 | The Efficacy and Safety RC48 Plus QL1706 in Second-Line Treatment of HER2-Expressing Recurrent CC | not yet recruiting | Phase 2 | 33 | Qilu Hospital of Shandong UniversityOTHER | 1 | Sep 15, 2025 | clinicaltrials |
| NCT07170982 | Fruquintinib Combined With Standard Chemotherapy Versus Standard Chemotherapy as First-line Treatment for Advanced pMMR Endometrial Cancer | not yet recruiting | Phase 2 | 128 | Sun Yat-sen UniversityOTHER | 1 | Sep 12, 2025 | clinicaltrials |
| NCT07141186 | QL1706 in Patients With Recurrent and Metastatic Cervical Cancer Resistant to Prior PD-1/PD-L1 Antibody Therapy | not yet recruiting | Phase 2 | 50 | Tianjin Medical University Cancer Institute and HospitalOTHER | 0 | Aug 26, 2025 | clinicaltrials |
| NCT07115927 | pReOperative Dostarlimab and Novel Therapies in EndOmetrial Cancer(RODEO) | not yet recruiting | Phase 2 | 40 | University College, LondonOTHER | 0 | Aug 19, 2025 | clinicaltrials |
| NCT06942377 | Calcium Channel Blocker Amlodipine for Endometrial Cancer Therapy | not yet recruiting | Phase 2 | 140 | Peking University People's HospitalOTHER | 1 | Jul 8, 2025 | clinicaltrials |
| NCT06073184 | Weight-loss Drug for Fertility-Sparing Treatment of Atypical Hyperplasia and Low-grade Cancer of the Endometrium(WE-FiERCE) | not yet recruiting | Phase 2 | 71 | University Health Network, TorontoOTHER | 0 | Jun 10, 2025 | clinicaltrials |
| NCT06986057 | Iparomlimab and Tuvonralimab Combined With Platinum-Based Chemotherapy for Neoadjuvant Treatment of Cervical Cancer | not yet recruiting | Phase 2 | 28 | Shandong Tumor HospitalOTHER | 0 | May 22, 2025 | clinicaltrials |
| NCT06981858 | A Single-Arm Exploratory Study of Enlansibumab Sequentially Combined With Concurrent Chemoradiotherapy for Locally Advanced Cervical Cancer | not yet recruiting | Phase 2 | 34 | Chongqing University Cancer HospitalOTHER | 0 | May 21, 2025 | clinicaltrials |
| NCT06976021 | Immune PET and Proteomics for the Assessment of Response to Spatially Fractionated or Palliative Radiotherapy With or Without Immunotherapy(INTROSPECTION) | not yet recruiting | Phase 2 | 60 | Maria Sklodowska-Curie National Research Institute of OncologyOTHER | 0 | May 16, 2025 | clinicaltrials |
| NCT06916117 | Neoadjuvant Chemo-immunotherapy Followed by Concurrent Chemoradiotherapy and Immunotherapy in LACC | not yet recruiting | Phase 2 | 30 | RenJi HospitalOTHER | 1 | Apr 8, 2025 | clinicaltrials |
| NCT06882447 | A Study of QL1706 Combined with Nine HPV Vaccine As First-line Treatment for Persistent, Recurrent or Metastatic Cervical Cancer(QL1706) | not yet recruiting | Phase 2 | 35 | Northern Jiangsu People's HospitalOTHER | 0 | Mar 28, 2025 | clinicaltrials |
| NCT06805864 | Pembrolizumab Concurrent With and Following Carbon-ion Radiotherapy for Locally Advanced Cervical Adenocarcinoma(BROTHER) | not yet recruiting | Phase 2 | 45 | Gunma UniversityOTHER | 1 | Feb 3, 2025 | clinicaltrials |
| NCT06783153 | Efficacy and Safety of Adjunctive Use of Rifaximin In Preventing Radiotherapy-induced Diarrhea in Cancer Patients | not yet recruiting | Phase 1 / Phase 2 | 80 | Mansoura UniversityOTHER | 1 | Jan 20, 2025 | clinicaltrials |
Data updated 24 hours agoSource updated Sep 28, 2026source: clinicaltrials